[ACOR] Acorda Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 1.15 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart ACOR

Refresh chart

Strongest Trends Summary For ACOR

ACOR is in the long-term down -70% below S&P in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea

Fundamental Ratios
Shares Outstanding46.07 M EPS-1.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.8% Sales Growth - Q/Q-15.29% P/E-14.87
P/E To EPS Growth P/S2.74 P/BV2.1 Price/Cash Per Share3.83
Price/Free Cash Flow16.48 ROA1.26% ROE2.53% ROI1.53%
Current Ratio3.47 Quick Ratio3.09 Long Term Debt/Equity0.96 Debt Ratio0.22
Gross Margin80.15% Operating Margin7.54% Net Profit Margin3.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.63 M Cash From Investing Activities-116.04 M Cash From Operating Activities-9.25 M Gross Profit90.84 M
Net Profit1000 K Operating Profit5.69 M Total Assets1.1 B Total Current Assets408.31 M
Total Current Liabilities460.01 M Total Debt292.68 M Total Liabilities540.27 M Total Revenue113.71 M
Technical Data
High 52 week32.6 Low 52 week13.8 Last close32.6 Last change7.24%
RSI96.12 Average true range1.73 Beta1.06 Volume622.39 K
Simple moving average 20 days27.01% Simple moving average 50 days34.29% Simple moving average 200 days35.16%
Performance Data
Performance Week23.72% Performance Month38.14% Performance Quart27.34% Performance Half57.11%
Performance Year92.9% Performance Year-to-date51.98% Volatility daily2.78% Volatility weekly6.22%
Volatility monthly12.76% Volatility yearly44.18% Relative Volume329.71% Average Volume497.09 K
New High New Low

News

2019-09-18 10:33:02 | Acceleron Discontinues Mid-Stage Muscular Dystrophy Study

2019-09-18 08:42:12 | Lexicon LXRX Catches Eye: Stock Jumps 7.3%

2019-09-18 07:00:00 | Acorda to Present Data at the International Congress of Parkinson’s Disease and Movement Disorders

2019-09-16 10:29:02 | Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

2019-09-13 10:30:02 | Celgene's CELG Leukemia Candidate Meets Endpoints in Study

2019-09-13 08:42:12 | Ligand LGND Surges: Stock Moves 6.3% Higher

2019-09-12 08:35:12 | Immunomedics IMMU Looks Good: Stock Adds 6.1% in Session

2019-09-11 11:37:03 | Ultragenyx to Submit sBLA for Label Expansion of Crysvita

2019-09-10 09:01:01 | Adaptimmune ADAP Gets Orphan Drug Status for T-cell Therapy

2019-09-10 07:59:11 | Horizon's HZNP Eye Disease Drug Gets FDA's Priority Review

2019-09-09 15:51:30 | Did Changing Sentiment Drive Acorda Therapeutics's NASDAQ:ACOR Share Price Down A Painful 91%?

2019-09-03 11:00:03 | Acorda ACOR Down More Than 60% in 3 Months: Here's Why

2019-08-31 09:32:01 | Why Is Acorda ACOR Down 46.8% Since Last Earnings Report?

2019-08-23 09:15:01 | Alexion Pharmaceuticals ALXN Jumps: Stock Rises 7.5%

2019-08-23 07:38:11 | Retrophin Down on Neurological Disorder Drug Study Failure

2019-08-21 18:03:10 | Synlogic Discontinues Development of SYNB1020, Stock Down

2019-08-21 08:42:12 | Moderna MRNA Jumps: Stock Rises 5.6%

2019-08-20 08:34:12 | Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment

2019-08-20 07:44:11 | Acorda Therapeutics Enters Oversold Territory

2019-08-14 09:10:01 | Kadmon KDMN Completes Enrollment in KD025 Study for cGVHD

2019-08-13 09:50:01 | Regeneron Ebola Treatment Shows Promise, Study Stopped Early

2019-08-12 08:37:12 | Epizyme EPZM Q2 Loss In Line, Revenues Beat Estimates

2019-08-09 11:09:03 | Agenus AGEN Q2 Earnings Miss Estimates, Revenues Beat

2019-08-08 10:45:02 | Immunomedics IMMU Posts Wider-Than-Expected Loss in Q2

2019-08-08 10:15:02 | Horizon Therapeutics' HZNP Q2 Earnings Beat Estimates

2019-08-08 09:26:01 | Catalyst's CPRX Q2 Earnings and Revenues Beat Estimates

2019-08-03 18:42:10 | Edited Transcript of ACOR earnings conference call or presentation 1-Aug-19 8:30pm GMT

2019-08-02 11:54:03 | Blueprint Medicines BPMC Q2 Loss Widens, Sales Top Mark

2019-08-02 10:53:02 | Acorda ACOR Q2 Earnings and Revenues Surpass Estimates

2019-08-02 10:52:02 | Emergent EBS Earnings Miss in Q2, Revenues Beat Estimates

2019-08-02 10:48:02 | Geron GERN Stock Up Despite Q2 Earnings & Sales Miss

2019-08-02 10:43:02 | IVERIC bio's ISEE Q2 Loss Narrows, Gene Therapy in Focus

2019-08-02 08:24:09 | Acorda Therapeutics ACOR Q2 2019 Earnings Call Transcript

2019-08-01 18:45:10 | Acorda Therapeutics ACOR Reports Q2 Loss, Tops Revenue Estimates

2019-08-01 16:00:00 | Acorda Provides Update for Second Quarter Ended June 30, 2019

2019-08-01 12:02:04 | Agios' AGIO Loss Widens in Q2, Tibsovo Drives Sales

2019-08-01 12:00:04 | Vertex VRTX Beats on Q2 Earnings, Ups CF Product Sales View

2019-08-01 09:54:01 | Amgen AMGN Catches Eye: Stock Jumps 5.7%

2019-07-31 11:32:03 | Celgene CELG Beats on Q2 Earnings, Raises Revenue Guidance

2019-07-26 10:38:02 | Alkermes ALKS Earnings and Sales Beat Estimates in Q2

2019-07-26 08:30:00 | Acorda Receives Positive CHMP Opinion for INBRIJA™ levodopa inhalation powder

2019-07-25 11:25:03 | Medicines Company MDCO Q2 Earnings Top, Inclisiran in View

2019-07-25 11:10:03 | Acorda ACOR to Post Q2 Earnings: What's in the Cards?

2019-07-25 10:33:02 | Analysts Estimate Acorda Therapeutics ACOR to Report a Decline in Earnings: What to Look Out for

2019-07-24 17:50:09 | Acorda Therapeutics ACOR Outpaces Stock Market Gains: What You Should Know

2019-07-24 13:54:05 | Alexion ALXN Q2 Earnings Beat Estimates, Guidance Raised

2019-07-19 09:41:01 | Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

2019-07-18 07:00:00 | Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled for August 1, 2019

2019-07-16 13:15:05 | Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study

2019-07-11 11:14:03 | FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug